More than one - third of patients with
metastatic uveal melanoma had objective tumor regression when treated with adoptive transfer of autologous tumor - infiltrating lymphocytes.
NEW YORK, NY (June 19, 2014)-- For the first time, a therapy has been found that can delay progression of
metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.
One hundred and one patients with
metastatic uveal melanoma at 15 centers in the United States and Canada were randomized to receive either selumetinib or standard chemotherapy.
The median survival rate for patients with
metastatic uveal melanoma is 12 months.
In the trial, researchers randomized 98 patients with
metastatic uveal melanoma and administered selumetinib to 47, of which 81 percent had a Gnaq or Gna11 mutation.
Not exact matches
But
uveal melanoma often spreads to the liver, and determining the
metastatic status of the disease can be difficult.
Though
uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop
metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.